Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 52

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 52
---
OGX, conversations regarding the proposed Merger were frequent, direct, and collaborative. See “ Interests of the TELO Directors, Executive Officers and Affiliate Shareholders in the Merger” on page 34 of this proxy statement for additional details.

On September 20, 2025, TELO conducted an introductory call with Moore Financial Consulting Ltd. (“Moore”) regarding conducting valuations of TELO and TELI for purposes of determining the Exchange Ratio to be used in the Merger based on the relative valuations of TELO and TELI.

On September 21, 2025, TELO and Moore provided TELI with a list of diligence questions related to TELI’s pipeline, clinical development plans, the competitive landscape, regulatory and commercial considerations. Additionally, Moore provided TELO with a list of diligence questions related to TELI’s pipeline, clinical development plans, the competitive landscape, regulatory and commercial considerations.

In October 2025, TELO engaged Moore to conduct a valuation of TELO and TELI for determination of the Exchange Ratio. On October 8, 2025, a first draft of a Binding Letter of Intent (LOI) was circulated between TELO and TELI.

On October 1, 2025, TELO provided Moore with preliminary responses to Moore’s questions, including estimated completion dates and general and administrative expense forecasts required for Telomir-1 for each of Phase 1, Phase 2, Phase 2a and Phase 3 for the FDA process, quarterly research and development expense forecasts. detailed forecast of TELO’s research and development and general administrative expenses through 2027.

On October 8, 2025, after significant information discussion, William McNulty continued on behalf of TELI to negotiate the terms of the Merger with TELO.

On October 9, 2025 a revised draft of the LOI was circulated between TELO and TELI.

On October 10, 2025, the TELO Board held a meeting to discuss the LOI. Mr. Aminov provided a presentation on TELI’s business and explained the potential synergies between the two companies and market potential of Telomir-1. Mr. Aminov also explained to the TELO Board the conflicts of interests involved in the Merger. The terms of the LOI and the Telomir-1 Licensing Agreement were also discussed and reviewed. The TELO Board approved the Merger and the terms of the LO